이상지질혈증 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Lipid Disorder Treatment Market (Drug Type: Atorvastatin, Fluvastatin, Rosuvastatin, Simvastatin, Pravastatin, and Other Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2023-2031

US $ 5,795 ￦ 8,366,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795 ￦ 12,698,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795 ￦ 17,029,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

이상지질혈증 치료 시장 - 리포트 대상 범위

세계의 이상지질혈증 치료 시장에 관한 TMR의 리포트에서는 과거와 현재의 성장 동향 및 2023-2031년의 예측 기간 중 시장 지표의 귀중한 인사이트를 얻을 기회를 조사하고 있습니다. 이 리포트는 세계의 이상지질혈증 치료 시장의 2017-2031년 기간의 매출을 제공하고, 2023년을 기준년, 2031년을 예측년으로 간주합니다. 또한 2023-2031년 세계 이상지질혈증 치료 시장의 연평균 성장률(CAGR %)도 제공하고 있습니다.

이 리포트는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 조사 활동의 대부분을 시행하고 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 제조업체와 인터뷰를 진행했습니다. 2차 조사에는 이상지질혈증 치료 시장을 이해하기 위해 주요 기업의 제품 문헌, 연차보고서, 프레스 릴리스 및 관련 문서의 참조가 포함됩니다.

이 리포트는 세계의 이상지질혈증 치료 시장의 경쟁 구도를 자세하게 조사하고 있습니다. 세계의 이상지질혈증 치료 시장에서 활동하는 주요 기업이 식별되고 각각의 기업이 다양한 속성의 관점에서 프로파일링되고 있습니다. 회사 개요, 재무 상황, 최근 동향, SWOT는 이 리포트에서 소개되고 있는 세계의 이상지질혈증 치료 시장 기업의 속성입니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

• 서론
• 개요
• 시장 역학
• 세계 시장의 분석과 예측(2017-2031년)

제5장 주요 인사이트

• 파이프라인 분석
• 주요 제품/브랜드 분석
• 주요 합병과 인수
• COVID-19 팬데믹이 업계에 미치는 영향

제6장 세계 시장의 분석과 예측 : 의약품 유형별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 금액 예측 : 의약품 유형별(2017-2031년)
  • Atorvastatin
  • Fluvastatin
  • Rosuvastatin
  • Simvastatin
  • Pravastatin
  • 기타 의약품
• 시장의 매력 분석 : 의약품 유형별

제7장 세계 시장의 분석과 예측 : 유통 채널별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 금액 예측 : 유통 채널별(2017-2031년)
  • 소매 약국
  • 원내 약국
  • 온라인 약국
• 시장의 매력 분석 : 유통 채널별

제8장 세계 시장의 분석과 예측 : 증상별

• 서론과 정의
• 주요 조사 결과/발전
• 시장 금액 예측 : 증상별(2017-2031년)
  • 가족성 복합형고지혈증
  • 가족성 결손 아포리포단백질 B-100
  • Familial Dysbetalipoproteinemia
  • 가족성 고중성지방혈증
  • 이형접합 가족성 고콜레스테롤혈증
  • 기타 증상
• 시장의 매력 분석 : 증상별

제9장 세계 시장의 분석과 예측 : 지역별

• 주요 조사 결과
• 시장 금액 예측 : 지역별(2017-2031년)
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역별

제10장 북미 시장 분석과 예측

제11장 유럽 시장 분석과 예측

제12장 아시아태평양 시장 분석과 예측

제13장 라틴아메리카 시장 분석과 예측

제14장 중동 및 아프리카 시장 분석과 예측

제15장 경쟁 구도

• 시장 기업 : 경쟁 매트릭스(기업 계층·규모별)
• 시장 점유율 분석 : 기업별(2022년)
• 기업 개요
  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca
  • Merck &Co., Inc.
  • Emcure Pharmaceuticals Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Mylan NV
  • Kowa Pharmaceuticals America, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Sun Pharmaceuticals Industries Ltd.
  • Wockhardt Limited

KSA

영문 목차

영문목차

Lipid Disorder Treatment Market - Scope of Report

TMR's report on the global lipid disorder treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global lipid disorder treatment market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lipid disorder treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the lipid disorder treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lipid disorder treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lipid disorder treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lipid disorder treatment market.

The report delves into the competitive landscape of the global lipid disorder treatment market. Key players operating in the global lipid disorder treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lipid disorder treatment market profiled in this report.

Key Questions Answered in Global lipid disorder treatment Market Report:

• What is the sales/revenue generated by lipid disorder treatment across all regions during the forecast period?
• What are the opportunities in the global lipid disorder treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Lipid Disorder Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global lipid disorder treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global lipid disorder treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lipid disorder treatment market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Lipid Disorder Treatment Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Lipid Disorder Treatment Market Analysis and Forecast, 2017-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Lipid Disorder Treatment Market Analysis and Forecast, by Drug Type

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Drug Type, 2017-2031
  • 6.3.1. Atorvastatin
  • 6.3.2. Fluvastatin
  • 6.3.3. Rosuvastatin
  • 6.3.4. Simvastatin
  • 6.3.5. Pravastatin
  • 6.3.6. Other Drugs
• 6.4. Market Attractiveness Analysis, by Drug Type

7. Global Lipid Disorder Treatment Market Analysis and Forecast, by Distribution Channel

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
  • 7.3.1. Retail Pharmacies
  • 7.3.2. Hospital Pharmacies
  • 7.3.3. Online Pharmacies
• 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Lipid Disorder Treatment Market Analysis and Forecast, by Indication

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Indication, 2017-2031
  • 8.3.1. Familial Combined Hyperlipidemia
  • 8.3.2. Familial Defective Apolipoprotein B-100
  • 8.3.3. Familial Dysbetalipoproteinemia
  • 8.3.4. Familial Hypertriglyceridemia
  • 8.3.5. Heterozygous Familial Hypercholesterolemia
  • 8.3.6. Other Indications
• 8.4. Market Attractiveness Analysis, by Indication

9. Global Lipid Disorder Treatment Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region, 2017-2031
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness Analysis, by Region

10. North America Lipid Disorder Treatment Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Drug Type, 2017-2031
  • 10.3.1. Atorvastatin
  • 10.3.2. Fluvastatin
  • 10.3.3. Rosuvastatin
  • 10.3.4. Simvastatin
  • 10.3.5. Pravastatin
  • 10.3.6. Other Drugs
• 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 10.4.1. Retail Pharmacies
  • 10.4.2. Hospital Pharmacies
  • 10.4.3. Online Pharmacies
• 10.5. Market Value Forecast, by Indication, 2017-2031
  • 10.5.1. Familial Combined Hyperlipidemia
  • 10.5.2. Familial Defective Apolipoprotein B-100
  • 10.5.3. Familial Dysbetalipoproteinemia
  • 10.5.4. Familial Hypertriglyceridemia
  • 10.5.5. Heterozygous Familial Hypercholesterolemia
  • 10.5.6. Other Indications
• 10.6. Market Value Forecast, by Country, 2017-2031
  • 10.6.1. U.S.
  • 10.6.2. Canada
• 10.7. Market Attractiveness Analysis
  • 10.7.1. By Drug Type
  • 10.7.2. By Distribution Channel
  • 10.7.3. By Indication
  • 10.7.4. By Country

11. Europe Lipid Disorder Treatment Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Drug Type, 2017-2031
  • 11.3.1. Atorvastatin
  • 11.3.2. Fluvastatin
  • 11.3.3. Rosuvastatin
  • 11.3.4. Simvastatin
  • 11.3.5. Pravastatin
  • 11.3.6. Other Drugs
• 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 11.4.1. Retail Pharmacies
  • 11.4.2. Hospital Pharmacies
  • 11.4.3. Online Pharmacies
• 11.5. Market Value Forecast, by Indication, 2017-2031
  • 11.5.1. Familial Combined Hyperlipidemia
  • 11.5.2. Familial Defective Apolipoprotein B-100
  • 11.5.3. Familial Dysbetalipoproteinemia
  • 11.5.4. Familial Hypertriglyceridemia
  • 11.5.5. Heterozygous Familial Hypercholesterolemia
  • 11.5.6. Other Indications
• 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.6.1. Germany
  • 11.6.2. U.K.
  • 11.6.3. France
  • 11.6.4. Italy
  • 11.6.5. Spain
  • 11.6.6. Rest of Europe
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Drug Type
  • 11.7.2. By Distribution Channel
  • 11.7.3. By Indication
  • 11.7.4. By Country/Sub-region

12. Asia Pacific Lipid Disorder Treatment Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Drug Type, 2017-2031
  • 12.3.1. Atorvastatin
  • 12.3.2. Fluvastatin
  • 12.3.3. Rosuvastatin
  • 12.3.4. Simvastatin
  • 12.3.5. Pravastatin
  • 12.3.6. Other Drugs
• 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 12.4.1. Retail Pharmacies
  • 12.4.2. Hospital Pharmacies
  • 12.4.3. Online Pharmacies
• 12.5. Market Value Forecast, by Indication, 2017-2031
  • 12.5.1. Familial Combined Hyperlipidemia
  • 12.5.2. Familial Defective Apolipoprotein B-100
  • 12.5.3. Familial Dysbetalipoproteinemia
  • 12.5.4. Familial Hypertriglyceridemia
  • 12.5.5. Heterozygous Familial Hypercholesterolemia
  • 12.5.6. Other Indications
• 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.6.1. China
  • 12.6.2. Japan
  • 12.6.3. India
  • 12.6.4. Australia & New Zealand
  • 12.6.5. Rest of Asia Pacific
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Drug Type
  • 12.7.2. By Distribution Channel
  • 12.7.3. By Indication
  • 12.7.4. By Country/Sub-region

13. Latin America Lipid Disorder Treatment Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Drug Type, 2017-2031
  • 13.3.1. Atorvastatin
  • 13.3.2. Fluvastatin
  • 13.3.3. Rosuvastatin
  • 13.3.4. Simvastatin
  • 13.3.5. Pravastatin
  • 13.3.6. Other Drugs
• 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 13.4.1. Retail Pharmacies
  • 13.4.2. Hospital Pharmacies
  • 13.4.3. Online Pharmacies
• 13.5. Market Value Forecast, by Indication, 2017-2031
  • 13.5.1. Familial Combined Hyperlipidemia
  • 13.5.2. Familial Defective Apolipoprotein B-100
  • 13.5.3. Familial Dysbetalipoproteinemia
  • 13.5.4. Familial Hypertriglyceridemia
  • 13.5.5. Heterozygous Familial Hypercholesterolemia
  • 13.5.6. Other Indications
• 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.6.1. Brazil
  • 13.6.2. Mexico
  • 13.6.3. Rest of Latin America
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Drug Type
  • 13.7.2. By Distribution Channel
  • 13.7.3. By Indication
  • 13.7.4. By Country/Sub-region

14. Middle East & Africa Lipid Disorder Treatment Market Analysis and Forecast

• 14.1. Introduction
• 14.2. Key Findings
• 14.3. Market Value Forecast, by Drug Type, 2017-2031
  • 14.3.1. Atorvastatin
  • 14.3.2. Fluvastatin
  • 14.3.3. Rosuvastatin
  • 14.3.4. Simvastatin
  • 14.3.5. Pravastatin
  • 14.3.6. Other Drugs
• 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
  • 14.4.1. Retail Pharmacies
  • 14.4.2. Hospital Pharmacies
  • 14.4.3. Online Pharmacies
• 14.5. Market Value Forecast, by Indication, 2017-2031
  • 14.5.1. Familial Combined Hyperlipidemia
  • 14.5.2. Familial Defective Apolipoprotein B-100
  • 14.5.3. Familial Dysbetalipoproteinemia
  • 14.5.4. Familial Hypertriglyceridemia
  • 14.5.5. Heterozygous Familial Hypercholesterolemia
  • 14.5.6. Other Indications
• 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.6.1. GCC Countries
  • 14.6.2. South Africa
  • 14.6.3. Rest of Middle East & Africa
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Drug Type
  • 14.7.2. By Distribution Channel
  • 14.7.3. By Indication
  • 14.7.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 15.2. Market Share Analysis, by Company (2022)
• 15.3. Company Profiles
  • 15.3.1. Pfizer Inc.
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. SWOT Analysis
    • 15.3.1.4. Financial Overview
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Novartis AG
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. SWOT Analysis
    • 15.3.2.4. Financial Overview
    • 15.3.2.5. Strategic Overview
  • 15.3.3. AstraZeneca
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. SWOT Analysis
    • 15.3.3.4. Financial Overview
    • 15.3.3.5. Strategic Overview
  • 15.3.4. Merck & Co., Inc.
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. SWOT Analysis
    • 15.3.4.4. Financial Overview
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Emcure Pharmaceuticals Ltd.
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. SWOT Analysis
    • 15.3.5.4. Financial Overview
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Teva Pharmaceuticals Industries Ltd.
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. SWOT Analysis
    • 15.3.6.4. Financial Overview
    • 15.3.6.5. Strategic Overview
  • 15.3.7. Mylan N.V.
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. SWOT Analysis
    • 15.3.7.4. Financial Overview
    • 15.3.7.5. Strategic Overview
  • 15.3.8. Kowa Pharmaceuticals America, Inc.
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. SWOT Analysis
    • 15.3.8.4. Financial Overview
    • 15.3.8.5. Strategic Overview
  • 15.3.9. Glenmark Pharmaceuticals Ltd.
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Product Portfolio
    • 15.3.9.3. SWOT Analysis
    • 15.3.9.4. Financial Overview
    • 15.3.9.5. Strategic Overview
  • 15.3.10. Sun Pharmaceuticals Industries Ltd.
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Product Portfolio
    • 15.3.10.3. SWOT Analysis
    • 15.3.10.4. Financial Overview
    • 15.3.10.5. Strategic Overview
  • 15.3.11. Wockhardt Limited
    • 15.3.11.1. Company Overview
    • 15.3.11.2. Product Portfolio
    • 15.3.11.3. SWOT Analysis
    • 15.3.11.4. Financial Overview
    • 15.3.11.5. Strategic Overview

관련자료